Sub menu

 

 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

1167 result(s) found, displaying 226 to 250

  • AusPAR: Trastucip and Tuzucip

    Australian public assessment report (AusPar)
    Trastucip and Tuzucip (trastuzumab) for the treatment of breast cancer and gastric cancer

  • AusPAR: Scemblix

    Australian public assessment report (AusPar)
    Scemblix (Asciminib) for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukaemia

  • AusPAR: Vabysmo

    Australian public assessment report (AusPar)
    Vabysmo (faricimab) for the treatment of neovascular age-related macular degeneration and diabetic macular oedema.

  • AusPAR: Ryaltris

    Australian public assessment report (AusPar)
    New AusPAR for RYALTRIS - olopatadine and mometasone furoate for allergic rhinitis and rhinoconjunctivitis.

  • AusPAR: Tecentriq

    Australian public assessment report (AusPar)
    AusPAR for Tecentriq (atezolizumab) for conversion of provisionally registered indication (for treatment of locally advanced or metastatic triple negative breast cancer (mTNBC)) to full registration (withdrawn).

  • AusPAR: Dupixent

    Australian public assessment report (AusPar)
    AusPAR for DUPIXENT dupilumab for the treatment of asthma.

  • AusPAR: RINVOQ

    Australian public assessment report (AusPar)
    AusPAR for RINVOQ (Upadacitinib) for treatment of atopic dermatitis in patients aged 12 years and above.

  • AusPAR: Eligard

    Australian public assessment report (AusPar)
    AusPAR for Eligard (Leuprorelin acetate) for the treatment of children with central precocious puberty (CPP).

  • AusPAR: Padcev

    Australian public assessment report (AusPar)
    AusPAR for Padcev (Enfortumab vedotin) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed receptor-1 or programmed death-ligand-1 inhibitor.

  • AusPAR: Maviret

    Australian public assessment report (AusPar)
    AusPAR for Maviret (glecaprevir /pibrentasvir) for the treatment of adult and paediatric patients with chronic hepatitis C virus.

  • AusPAR: Spikevax bivalent Original/Omicron BA.4-5

    Australian public assessment report (AusPar)
    AusPAR for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) as booster dose for active immunisation to prevent COVID-19

  • AusPAR: Bijuva 1/100

    Australian public assessment report (AusPar)
    AusPAR for Bijuva 1/100 (estradiol hemihydrate and progesterone) for use during HRT for estrogen deficiency symptoms.

  • AusPAR: Vumerity

    Australian public assessment report (AusPar)
    New AusPAR for VUMERITY (diroximel fumarate) to reduce relapses and delay progression of disability in multiple sclerosis patients.

  • AusPAR: Jemperli

    Australian public assessment report (AusPar)
    New AusPAR for Jemperli (dostarlimab) for the treatment of mismatch repair deficient endometrial cancer.

  • AusPAR: Vyxeos

    Australian public assessment report (AusPar)
    New AusPAR for Vyxeos (daunorubicin and cytarabine) for the treatment of acute myeloid leukaemia.

  • AusPAR: Vaxelis

    Australian public assessment report (AusPar)
    New AusPAR for Vaxelis (DTPa5-Hep B-IPV-Hib) for primary and booster vaccination.

  • AusPAR: Voxzogo

    Australian public assessment report (AusPar)
    AusPAR for Voxzogo (vosoritide) for the treatment of achondroplasia.

  • AusPAR: Ngenla

    Australian public assessment report (AusPar)
    AusPAR for Ngenla (somatrogon) for treatment of paediatric patients with growth disturbance due to insufficient growth hormone.

  • AusPAR: Xembify

    Australian public assessment report (AusPar)
    AusPAR for Xembify (human normal immunoglobulin) for the treatment of primary immunodeficiency diseases.

  • AusPAR: Evusheld

    Australian public assessment report (AusPar)
    AusPAR for Evusheld (tixagevimab and cilgavimab) for treatment of adults with COVID-19.

  • AusPAR: Kozenis

    Australian public assessment report (AusPar)
    AusPAR for Kozenis (tafenoquine) for prevention of relapse of Plasmodium vivax malaria in combination with chloroquine.

  • AusPAR: Nexviazyme

    Australian public assessment report (AusPar)
    AusPAR for NEXVIAZYME (avalglucosidase alfa) for long-term enzyme replacement therapy for the treatment of Pompe disease.

  • AusPAR: Truseltiq

    Australian public assessment report (AusPar)
    AusPAR for Truseltiq (infigratinib) for treatment of adults with metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement.